Adherence with advice and prescriptions in SLE is mostly good, but better follow up is needed: A study with a questionnaire
暂无分享,去创建一个
O. Nived | G. Sturfelt | M. Lindgren | K. Nived | A. Bengtsson | M. Andersson | C. Ståhl-Hallengren | A. Nihlberg | P. Malcus-Johnsson | G. Reimer-Rasmusson | Gunnar K Sturfelt | Anders A. Bengtsson
[1] W. Kannel,et al. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. , 2020, Annals of internal medicine.
[2] M. Liang,et al. Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. , 2005, Arthritis and rheumatism.
[3] P. Sloane,et al. Patients' perceptions of primary care physicians' participatory decision-making style and communication about complementary and alternative medicine for arthritis. , 2005, Journal of alternative and complementary medicine.
[4] J. Frostegård,et al. SLE, atherosclerosis and cardiovascular disease , 2005, Journal of internal medicine.
[5] M. Suarez‐Almazor,et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. , 2005, The Journal of rheumatology.
[6] H. Zeidler,et al. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. , 2005, The Journal of rheumatology.
[7] A. Boonen. Everyone has the right to work. , 2005, The Journal of rheumatology.
[8] A. Hingorani,et al. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. , 2004, Rheumatology.
[9] F. Granath,et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. , 2004, The Journal of rheumatology.
[10] J. Schwartz,et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. , 2003, The New England journal of medicine.
[11] I. Bruce,et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. , 2003, Arthritis and rheumatism.
[12] M. Ward,et al. Time perspective predicts the progression of permanent organ damage in patients with systemic lupus erythematosus , 2003, Lupus.
[13] O. Nived,et al. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. , 2002, Rheumatology.
[14] K. Asplund,et al. Use of complementary and alternative medicine remedies in Sweden. A population‐based longitudinal study within the northern Sweden MONICA Project , 2001, Journal of internal medicine.
[15] M. Ward,et al. Mortality and causes of death in systemic lupus erythematosus , 2001, Current opinion in rheumatology.
[16] Y. Brandberg,et al. Beliefs, knowledge and attitudes as predictors of sunbathing habits and use of sun protection among Swedish adolescents , 2001, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[17] R. D'Agostino,et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.
[18] C. Aranow,et al. Epidemiology of cardiovascular disease in systemic lupus erythematosus , 2000, Lupus.
[19] L. Vilá,et al. Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus. , 1999, Puerto Rico health sciences journal.
[20] I. Bruce,et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. , 1999, The Journal of rheumatology.
[21] D. Gladman,et al. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. , 1998, The Journal of rheumatology.
[22] T. Davis,et al. Literacy in patients with a chronic disease: systemic lupus erythematosus and the reading level of patient education materials. , 1997, The Journal of rheumatology.
[23] M. Liang,et al. Risk factors for early work disability in systemic lupus erythematosus: results from a multicenter study. , 1997, Arthritis and rheumatism.
[24] D. Gladman,et al. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. , 1997, The Journal of rheumatology.
[25] L. Hy,et al. Prednisolone non-compliance and its related factors in patients with systemic lupus erythematosus. , 1995 .
[26] M. Petri,et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. , 1992, The American journal of medicine.
[27] D. Isenberg,et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. , 1992, Annals of the rheumatic diseases.
[28] D. Wallace,et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. , 1990, The American journal of medicine.
[29] M. Hochberg,et al. Systemic lupus erythematosus. , 1990, Rheumatic diseases clinics of North America.
[30] A. Silman,et al. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. , 1990, British journal of rheumatology.
[31] M. Urowitz,et al. The bimodal mortality pattern of systemic lupus erythematosus. , 1976, The American journal of medicine.
[32] J. Deckers,et al. Smoking behaviour in European patients with established coronary heart disease. , 2006, European heart journal.
[33] D. Upchurch,et al. Use of complementary and alternative medicine among American women. , 2005, Women's health issues : official publication of the Jacobs Institute of Women's Health.
[34] J Thumboo,et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. , 1999, Arthritis and rheumatism.
[35] O. Nived,et al. Epidemiology of systemic lupus erythematosus. , 1987, Monographs in allergy.
[36] J. Paterson. Serum Lipoproteins and Coronary Artery Disease. , 1957, Canadian Medical Association journal.